Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 155

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 16C
Chunk 155
---
20-F for the year-ended December 31, 2023 relating to the design and maintenance of effective controls to assess and account for royalty revenue reduction provisions within agreements with collaboration partners.

Genmab has provided PwC with a copy of the foregoing disclosure under this Item 16F and has requested PwC to furnish Genmab with a letter addressed to the Securities and Exchange Commission stating whether or not PwC agrees with such disclosure. A copy of PwC's letter dated February 12, 2025 is provided as Exhibit 15.4 of this Annual Report on Form 20-F.

During the years ended December 31, 2023 and 2022 and through March 13, 2024, neither Genmab nor anyone on its behalf consulted Deloitte in relation to either: (1) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on Genmab’s consolidated financial statements and neither a written report was provided to Genmab or oral advice was provided that Deloitte concluded was an important factor considered by Genmab in reaching a decision as to the accounting, auditing or financial reporting issue or (2) any matter that was either the subject of a disagreement (as defined in Item 16F(a)(1)(iv)) of Form 20-F or a reportable event as that term is defined in Item 16F(a)(1)(v) of Form 20-F.

ITEM 16G CORPORATE GOVERNANCE

The listing rules of the Nasdaq (the “Nasdaq Listing Rules”) provide that foreign private issuers may follow home country practice in lieu of Nasdaq Global Select Market corporate governance standards, subject to certain exceptions and except to the extent that such exemptions would be contrary to U. S. federal securities laws. The home country practices we follow in lieu of the Nasdaq Listing Rules are described below.

  We do not follow the quorum requirements of the Nasdaq Stock Market applicable to meetings of shareholders. In accordance with Danish corporate law and generally accepted business practice, our...  

  We do not follow the requirements of the Nasdaq Stock Market regarding the provision of proxy statements for general meetings of shareholders. Danish corporate law does not have a regulatory re...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We do not follow the requirements of the Nasdaq